The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study of OSI-906, dual tyrosine kinase inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR) in combination with erlotinib (E) in patients with advanced solid tumors.
V. M. Macaulay
Consultant or Advisory Role - OSI Pharmaceuticals; Roche
M. R. Middleton
No relevant relationships to disclose
S. G. Eckhardt
Consultant or Advisory Role - OSI Pharmaceuticals
Research Funding - OSI Pharmaceuticals
R. A. Juergens
Research Funding - OSI Pharmaceuticals
C. M. Rudin
Consultant or Advisory Role - Genentech; Novartis; Syndax
A. Manukyants
Employment or Leadership Position - OSI Pharmaceuticals
S. Gogov
Employment or Leadership Position - OSI Pharmaceuticals
Stock Ownership - OSI Pharmaceuticals
S. Poondru
Employment or Leadership Position - OSI Pharmaceuticals
Stock Ownership - OSI Pharmaceuticals
R. Gedrich
Employment or Leadership Position - Astellas Pharma
Stock Ownership - Astellas Pharma
S. M. Gadgeel
Consultant or Advisory Role - OSI Pharmaceuticals
Honoraria - OSI Pharmaceuticals